FI58435C - Foerfarande foer framstaellning av en intravenoesduglig sulfonamid och sulfonamidaktivator innehaollande vattenhaltig infusionloesning - Google Patents
Foerfarande foer framstaellning av en intravenoesduglig sulfonamid och sulfonamidaktivator innehaollande vattenhaltig infusionloesning Download PDFInfo
- Publication number
- FI58435C FI58435C FI781858A FI781858A FI58435C FI 58435 C FI58435 C FI 58435C FI 781858 A FI781858 A FI 781858A FI 781858 A FI781858 A FI 781858A FI 58435 C FI58435 C FI 58435C
- Authority
- FI
- Finland
- Prior art keywords
- solution
- och
- vattenhaltig
- sulphonamidaktivator
- intravenoesduglig
- Prior art date
Links
- 239000000243 solution Substances 0.000 description 35
- 229940124530 sulfonamide Drugs 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 150000003456 sulfonamides Chemical class 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 10
- 239000000600 sorbitol Substances 0.000 description 10
- 235000010356 sorbitol Nutrition 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000003978 infusion fluid Substances 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 239000005715 Fructose Substances 0.000 description 5
- 229930091371 Fructose Natural products 0.000 description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 150000005846 sugar alcohols Chemical class 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 125000001701 trimethoxybenzyl group Chemical group 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000037358 bacterial metabolism Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- -1 sulfonamide salt Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2731013A DE2731013C2 (de) | 1977-07-08 | 1977-07-08 | Verfahren zur Herstellung einer wäßrigen Infusionslösung |
| DE2731013 | 1977-07-08 | ||
| AT498477A AT351166B (de) | 1977-07-08 | 1977-07-12 | Verfahren zur herstellung einer gut ver- traeglichen, intravenoes zu verabreichenden, waessrigen loesung |
| AT498477 | 1977-07-12 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI781858A7 FI781858A7 (fi) | 1979-01-09 |
| FI58435B FI58435B (fi) | 1980-10-31 |
| FI58435C true FI58435C (fi) | 1981-02-10 |
Family
ID=25601735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI781858A FI58435C (fi) | 1977-07-08 | 1978-06-09 | Foerfarande foer framstaellning av en intravenoesduglig sulfonamid och sulfonamidaktivator innehaollande vattenhaltig infusionloesning |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4327084A (cs) |
| JP (1) | JPS5417109A (cs) |
| AT (1) | AT351166B (cs) |
| BE (1) | BE862348A (cs) |
| CH (1) | CH637826A5 (cs) |
| CS (1) | CS208479B2 (cs) |
| DD (1) | DD138506A1 (cs) |
| DE (1) | DE2731013C2 (cs) |
| DK (1) | DK159957C (cs) |
| FI (1) | FI58435C (cs) |
| FR (1) | FR2396550A1 (cs) |
| GB (1) | GB1561562A (cs) |
| IE (1) | IE47876B1 (cs) |
| LU (1) | LU79930A1 (cs) |
| NL (1) | NL179704C (cs) |
| ZA (1) | ZA783677B (cs) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH647412A5 (de) * | 1980-03-25 | 1985-01-31 | Hoffmann La Roche | Pharmazeutische praeparate. |
| FI871447A7 (fi) * | 1986-04-07 | 1987-10-08 | Bristol Myers Co | Stabila injicerbara antivomitiva kompositioner. |
| GB8617482D0 (en) * | 1986-07-17 | 1986-08-28 | Geistlich Soehne Ag | Pharmaceutical composition |
| DE4331147A1 (de) * | 1993-09-14 | 1995-03-16 | Nycomed Arzneimittel Gmbh | Intravenös verabreichbare, wäßrige Lösung |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH544053A (de) * | 1966-05-09 | 1973-11-15 | Hoffmann La Roche | Verfahren zur Herstellung von Sulfonamidderivaten |
| SE322866B (cs) * | 1966-12-15 | 1970-04-20 | Astra Ab | |
| US3637640A (en) * | 1970-05-04 | 1972-01-25 | Diagnostic Data Inc | Orgotein stabilized with saccharide process and products |
| JPS4911403B1 (cs) * | 1970-12-29 | 1974-03-16 | ||
| GB1469521A (en) * | 1973-01-05 | 1977-04-06 | Wellcome Found | Antimicrobial preparations |
-
1977
- 1977-07-08 DE DE2731013A patent/DE2731013C2/de not_active Expired
- 1977-07-12 AT AT498477A patent/AT351166B/de not_active IP Right Cessation
- 1977-12-27 BE BE183867A patent/BE862348A/xx not_active IP Right Cessation
-
1978
- 1978-03-08 GB GB9224/78A patent/GB1561562A/en not_active Expired
- 1978-06-01 DK DK243378A patent/DK159957C/da not_active IP Right Cessation
- 1978-06-09 FI FI781858A patent/FI58435C/fi not_active IP Right Cessation
- 1978-06-15 FR FR7817909A patent/FR2396550A1/fr active Granted
- 1978-06-20 NL NLAANVRAGE7806664,A patent/NL179704C/xx not_active IP Right Cessation
- 1978-06-27 IE IE1283/78A patent/IE47876B1/en not_active IP Right Cessation
- 1978-06-27 ZA ZA00783677A patent/ZA783677B/xx unknown
- 1978-07-06 LU LU79930A patent/LU79930A1/xx unknown
- 1978-07-06 DD DD78206566A patent/DD138506A1/xx not_active IP Right Cessation
- 1978-07-06 JP JP8151578A patent/JPS5417109A/ja active Granted
- 1978-07-07 CS CS784554A patent/CS208479B2/cs unknown
- 1978-07-07 CH CH743778A patent/CH637826A5/de not_active IP Right Cessation
-
1979
- 1979-10-26 US US06/088,651 patent/US4327084A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| NL7806664A (nl) | 1979-01-10 |
| FR2396550B1 (cs) | 1980-06-13 |
| IE781283L (en) | 1979-01-08 |
| ZA783677B (en) | 1979-07-25 |
| NL179704C (nl) | 1986-11-03 |
| FR2396550A1 (fr) | 1979-02-02 |
| DD138506A1 (de) | 1979-11-07 |
| BE862348A (fr) | 1978-06-27 |
| GB1561562A (en) | 1980-02-27 |
| FI58435B (fi) | 1980-10-31 |
| LU79930A1 (cs) | 1978-12-07 |
| DK243378A (da) | 1979-01-09 |
| JPS5417109A (en) | 1979-02-08 |
| FI781858A7 (fi) | 1979-01-09 |
| AT351166B (de) | 1979-07-10 |
| CS208479B2 (en) | 1981-09-15 |
| DK159957C (da) | 1991-05-27 |
| JPS5639285B2 (cs) | 1981-09-11 |
| DE2731013A1 (de) | 1979-01-11 |
| US4327084A (en) | 1982-04-27 |
| DE2731013C2 (de) | 1982-07-15 |
| CH637826A5 (de) | 1983-08-31 |
| IE47876B1 (en) | 1984-07-11 |
| DK159957B (da) | 1991-01-07 |
| NL179704B (nl) | 1986-06-02 |
| ATA498477A (de) | 1978-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU226778B1 (en) | Injection and injection kit containing omeprazole and its analogs | |
| US9427398B2 (en) | Parenteral solutions containing metolazone | |
| Churchill et al. | Nephrotoxicity associated with combined gentamicin–amphotericin B therapy | |
| FI58435C (fi) | Foerfarande foer framstaellning av en intravenoesduglig sulfonamid och sulfonamidaktivator innehaollande vattenhaltig infusionloesning | |
| KR0178794B1 (ko) | 산화형 글루타티온 알킬 에스테르 | |
| US4181731A (en) | Novel therapeutic application of 4-carbamoyl-5-hydroxyimidazole | |
| US4698361A (en) | Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same | |
| US4002741A (en) | Meglumine complex fungicidal polyene macrolide antibiotic compositions and treatment method | |
| US5281588A (en) | Organometallic compounds, methods for their preparation and pharmaceutical compositions containing them | |
| US4719213A (en) | Anti-cancer composition for delivering 5-fluorouracil | |
| US20250000819A1 (en) | Anti-hypoxic/anoxic injury use of a magnolol and/or honokiol aromatic ring amino-substituted derivative, and a pharmaceutical composition | |
| US4968673A (en) | Use of a thromboxane receptor antagonist in renal diseases and dysfunction | |
| GB2030863A (en) | Antibacterial compositions | |
| US4892876A (en) | Method for inhibiting HIV and an pharmaceutical composition therefor | |
| IL80787A (en) | Pharmaceutical compositions containing derivatives of acetic acid anhydride and a process for preparing such compositions | |
| US3519712A (en) | Therapeutic compositions comprising n-methylglucamine and coumermycin or salts thereof | |
| US3299124A (en) | Tetracycline cyclohexyl sulphamate and process for preparation | |
| US4981852A (en) | Chemical compounds triamterene and hydrochlorothiazide | |
| EP0312132B1 (en) | Veterinary and human medical remedy having an antiviral and antitumorous activity, containing 2,6-diamino-3-phenyl-azo-pyridine | |
| US6060498A (en) | Composition containing antitumor agent | |
| US3906107A (en) | Aminoalkyl sulfate esters with diuretic activity | |
| DE3843059A1 (de) | Waessrige formulierungen, die ein piperidinylcyclopentylheptensaeure-derivat enthalten | |
| US4007166A (en) | Meglumine complexes of fungicidal polyene macrolide antibiotics and method of preparing same | |
| Kneer | Pharmacokinetic properties of new oral cephalosporins | |
| KR20050022250A (ko) | 녹차카테킨을 유효성분으로 포함하는 간 기능 개선제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MA | Patent expired | ||
| MA | Patent expired |
Owner name: HAFSLUND NYCOMED PHARMA |